AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03193320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid therapy protocol
Description: Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
Study NCT04266834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case.
Study NCT03709368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hardware
Description: Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
Study NCT03709368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hardware
Description: Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
Study NCT03709368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLTS
Description: CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
Study NCT03709368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLTS
Description: CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
Study NCT03709368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PHAST
Description: PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
Study NCT02497820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place.
Study NCT01927536 — intervention group
Intervention type: DEVICE
Intervention: White LED Flashlight
Description: white light setting
Study NCT01927536 — intervention group
Intervention type: DEVICE
Intervention: Red/Green Green Dominant LED Flashlight
Description: Green LED light dominant setting
Study NCT03709368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAST
Description: PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
Study NCT01409850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aqualizer
Description: The Aqualizer is a soft splint with water-filled pads.
Study NCT01409850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft splint
Study NCT03709368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RANAS
Description: Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
Study NCT00322556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulins Intravenous (Human)
Description: Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
Study NCT00838474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: music
Description: Each infant was randomized to receive music therapy or no music over 2 consecutive days
Study NCT01446913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP Intervention
Study NCT01446913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced CPAP Intervention
Study NCT03709368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mini-RANAS
Description: Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
Study NCT01021150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombrabulin (AVE8062)
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion
Study NCT01021150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form: injection solution~Route of administration: intravenous infusion
Study NCT02621515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
Study NCT00860028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Varenicline Pretreatment
Description: 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
Study NCT00860028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term Varenicline Pretreatment
Description: 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
Study NCT04058483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotizability testing
Description: Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
Study NCT01725477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylen blue &normal saline
Description: Washing after dye injection
Study NCT01725477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Study NCT01725477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Study NCT01725477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metheylne blue with normal saline
Study NCT03974633 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection
Description: All information is included in the Arm/group descriptions
Study NCT03974633 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: All information is included in the Arm/group descriptions
Study NCT01754259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
Study NCT01754259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
Study NCT03154320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-Day Treatment
Description: Treatment with ART or TB medication on day of HIV diagnosis
Study NCT03154320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study NCT01007916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
Study NCT03709368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo poster
Description: One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
Study NCT01007916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lens
Description: Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
Study NCT04228302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral capsule
Description: 5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo.
Study NCT04228302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
Study NCT04088695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video through a web page
Description: Participants will see a video about blood donation.
Study NCT04088695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative text
Description: Participants will see a brief text about blood donation.
Study NCT01686555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Tablet
Study NCT01686555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT03120962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone 20mg/day, for 4 weeks
Study NCT03120962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
Study NCT03120962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
Study NCT03120962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 500mg three-times daily for 7 days
Study NCT01093690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
Study NCT01093690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
Study NCT01862614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Hydrochloride + Epinephrine
Study NCT01862614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Articaine Hydrochloride + Epinephrine
Study NCT00674258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, TTK and KOC1
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT01588847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with Bupivacaine hyperbar 0.5 %
Description: Spinal anesthesia with Bupivacaine hyperbar 0.5 %
Study NCT01588847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
Description: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
Study NCT03120962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famciclovir
Description: Famciclovir 500mg three-times daily for 7 days
Study NCT00293267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir potassium
Description: Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
Study NCT00293267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
Study NCT02331862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
Study NCT00447148 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: 3-dimensional coronary angiography
Description: 3-dimensional coronary angiography
Study NCT01067170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Stockings
Description: Thigh-high pneumatic compression stockings
Study NCT00483184 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Veldona,
Description: Very low dose oral natural human interferon alpha lozenges
Study NCT00483184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Veldona,
Description: Very low dose oral natural human interferon alpha lozenges
Study NCT01050816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chondron(autologous chondrocyte) Implantation
Description: * Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~\*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation.
Study NCT02660710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: maximum of 6-8 cycles of R-CHOP over 18-24 weeks
Study NCT00248781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecommunications system
Study NCT00248781 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: attention control
Description: health education
Study NCT03978234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 300 UNT
Description: AbobotulinumtoxinA 300 UNT
Study NCT03078348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test (FIT) Kit
Description: Free FIT Kits distributed at study entry.
Study NCT03078348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally targeted Photo Novella Booklet
Description: Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
Study NCT03078348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen for Life Brochure
Description: Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
Study NCT02816151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Study NCT02816151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Study NCT01970462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin prior to hospital discharge and 6 weeks following discharge.
Study NCT01970462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
Study NCT03311412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
Study NCT03311412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
Study NCT03311412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.